{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shenoy C"],"funding":["NHLBI NIH HHS","National Institutes of Health"],"pagination":["71-80"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8720142"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(1)"],"pubmed_abstract":["<h4>Aims</h4>Cardiovascular magnetic resonance (CMR) imaging is a key diagnostic tool for the evaluation of patients with suspected cardiac tumours. Patient management is guided by the CMR diagnosis, including no further testing if a mass is excluded or if only a pseudomass is found. However, there are no outcomes studies validating this approach.<h4>Methods and results</h4>In this multicentre study of patients undergoing clinical CMR for suspected cardiac tumour, CMR diagnoses were assigned as no mass, pseudomass, thrombus, benign tumour, or malignant tumour. A final diagnosis was determined after follow-up using all available data. The primary endpoint was all-cause mortality. Among 903 patients, the CMR diagnosis was no mass in 25%, pseudomass in 16%, thrombus in 16%, benign tumour in 17%, and malignant tumour in 23%. Over a median of 4.9 years, 376 patients died. Compared with the final diagnosis, the CMR diagnosis was accurate in 98.4% of patients. Patients with CMR diagnoses of pseudomass and benign tumour had similar mortality to those with no mass, whereas those with malignant tumour [hazard ratio (HR) 3.31 (2.40-4.57)] and thrombus [HR 1.46 (1.00-2.11)] had greater mortality. The CMR diagnosis provided incremental prognostic value over clinical factors including left ventricular ejection fraction, coronary artery disease, and history of extracardiac malignancy (P < 0.001).<h4>Conclusion</h4>In patients with suspected cardiac tumour, CMR has high diagnostic accuracy. Patients with CMR diagnoses of no mass, pseudomass, and benign tumour have similar long-term mortality. The CMR diagnosis is a powerful independent predictor of mortality incremental to clinical risk factors."],"journal":["European heart journal"],"pubmed_title":["Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study."],"pmcid":["PMC8720142"],"funding_grant_id":["R01HL64726","R01 HL064726","K23HL132011","K23 HL132011"],"pubmed_authors":["Grizzard JD","Zagurovskaya M","Kassi M","Kim HW","Parker MA","Shah DJ","Kim RJ","Shenoy C","Reardon MJ"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study.","description":"<h4>Aims</h4>Cardiovascular magnetic resonance (CMR) imaging is a key diagnostic tool for the evaluation of patients with suspected cardiac tumours. Patient management is guided by the CMR diagnosis, including no further testing if a mass is excluded or if only a pseudomass is found. However, there are no outcomes studies validating this approach.<h4>Methods and results</h4>In this multicentre study of patients undergoing clinical CMR for suspected cardiac tumour, CMR diagnoses were assigned as no mass, pseudomass, thrombus, benign tumour, or malignant tumour. A final diagnosis was determined after follow-up using all available data. The primary endpoint was all-cause mortality. Among 903 patients, the CMR diagnosis was no mass in 25%, pseudomass in 16%, thrombus in 16%, benign tumour in 17%, and malignant tumour in 23%. Over a median of 4.9 years, 376 patients died. Compared with the final diagnosis, the CMR diagnosis was accurate in 98.4% of patients. Patients with CMR diagnoses of pseudomass and benign tumour had similar mortality to those with no mass, whereas those with malignant tumour [hazard ratio (HR) 3.31 (2.40-4.57)] and thrombus [HR 1.46 (1.00-2.11)] had greater mortality. The CMR diagnosis provided incremental prognostic value over clinical factors including left ventricular ejection fraction, coronary artery disease, and history of extracardiac malignancy (P < 0.001).<h4>Conclusion</h4>In patients with suspected cardiac tumour, CMR has high diagnostic accuracy. Patients with CMR diagnoses of no mass, pseudomass, and benign tumour have similar long-term mortality. The CMR diagnosis is a powerful independent predictor of mortality incremental to clinical risk factors.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-06-04T03:01:03.649Z","creation":"2025-04-04T19:40:52.958Z"},"accession":"S-EPMC8720142","cross_references":{"pubmed":["34545397"],"doi":["10.1093/eurheartj/ehab635"]}}